secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2025-02-28T23:59:59+00:00
Accession:  0001104659-25-018636
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma regains Nasdaq compliance with $2.5M equity rule; under monitoring until Feb 2026
--------------------------------------------------------------------------------

- Received Nasdaq confirmation on Feb 25, 2025 of compliance with minimum $2.5M stockholders' equity requirement.
- Subject to mandatory panel monitoring through Feb 25, 2026; future non-compliance may lead to delisting without cure period.
- Closed $20M gross proceeds offering on Dec 30, 2024 to strengthen financial position.
- CEO cites potential transformational year ahead with bird flu/influenza antiviral pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925018636/0001104659-25-018636-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925018636/tm257866d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-018636

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer